Savara Inc. (SVRA) Reports Q1 Financial Results

Savara Inc. (NASDAQ:SVRA) is one of the 10 Best Penny Stocks to Buy for Long Term.

On May 12, 2026, Savara Inc. (NASDAQ:SVRA) reported Q1 EPS of (15c), versus the consensus estimate of (14c). Chair and CEO Matt Pauls said the company ended the quarter with approximately $203M in cash and expects to have access to as much as $150M in additional non-dilutive funding through debt and royalty financing structures if MOLBREEVI receives approval. Management said this positions the company to support global commercial launch activities. Pauls added that preparations ahead of the November 22 PDUFA date are accelerating, with the company’s Rare Disease Specialist team already focused on increasing awareness of autoimmune PAP and advancing launch readiness for MOLBREEVI, which could become the first approved treatment for the disease.

Last month, Oppenheimer analyst Mazahir Alimohamed assumed coverage of Savara Inc. (NASDAQ:SVRA) with an Outperform rating and raised the firm’s price target to $11 from $9. The firm said the company’s investment story is increasingly centered on regulatory execution and commercialization following the FDA’s Priority Review for the BLA submission of molgramostim, an inhaled GM-CSF therapy. Oppenheimer added that data from the Phase 3 IMPALA-2 study in autoimmune PAP support a high-probability approval outlook, noting that prior FDA feedback was primarily related to chemistry, manufacturing, and controls.

Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on therapies for rare respiratory diseases.

While we acknowledge the risk and potential of SVRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SVRA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1